Citation Impact
Citing Papers
Intracellular Tumor-Associated Antigens Represent Effective Targets for Passive Immunotherapy
2012 StandoutNobel
Immune Rejection of Mouse Tumors Expressing Mutated Self
2009 StandoutNobel
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
2003 StandoutNobel
Recognition of a Ubiquitous Self Antigen by Prostate Cancer-Infiltrating CD8 + T Lymphocytes
2008 StandoutScienceNobel
Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals
2010 StandoutNobel
Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes
2006 StandoutScience
Dendritic Cell Targeting of Survivin Protein in a Xenogeneic Form Elicits Strong CD4+ T Cell Immunity to Mouse Survivin
2006 StandoutNobel
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
1998 Standout
Dendritic Cells Infected with PoxvIn Vitro iruses Encoding MART-1/ Melan A Sensitize T Lymphocytes In Vitro
1997
Analysis of the T cell response to tumor and viral peptide antigens by an IFNγ-ELISPOT assay
1997
Innate and adaptive immune cells in the tumor microenvironment
2013 Standout
Active immunization against cancer with dendritic cells: The near future
2001 StandoutNobel
Tumour immunity: effector response to tumour and role of the microenvironment
2008
Imaging in the era of molecular oncology
2008 StandoutNature
Tumor immunity and autoimmunity induced by immunization with homologous DNA.
1998
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
2015 Standout
Cancer immunotherapy via dendritic cells
2012 Standout
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
1998 Standout
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
2003 Standout
Immunity to cancer: attack and escape in T lymphocyte–tumor cell interaction
2002
Myeloid-derived suppressor cells as regulators of the immune system
2009 Standout
Cancer vaccines based on the identification of genes encoding cancer regression antigens
1997
Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells
1999 StandoutNobel
Real-Time Quantitative Polymerase Chain Reaction Assessment of Immune Reactivity in Melanoma Patients After Tumor Peptide Vaccination
2000
The immunologic constant of rejection
2008
Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells
1999 StandoutNobel
Detection and quantification of CD8+ T cells specific for HLA-A*0201-binding melanoma and viral peptides by the IFN-?-elispot assay
2001
Cancer immunotherapy: moving beyond current vaccines
2004 Standout
Hematopoietic Stem-Cell Transplantation
2006 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
T Cell Surveillance of Oncogene-Induced Prostate Cancer Is Impeded by T Cell-Derived TGF-β1 Cytokine
2011 StandoutNobel
Cancer immunotherapy comes of age
2011 StandoutNature
Regulatory T cells in tumor immunity
2010 StandoutNobel
Regulatory T cells in cancer immunotherapy
2014 StandoutNobel
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
2013 Standout
A New Era for Cancer Immunotherapy Based on the Genes that Encode Cancer Antigens
1999
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
2012 StandoutNatureNobel
Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells
2005 StandoutNobel
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
2001 StandoutNature
Immunizing Patients With Metastatic Melanoma Using Recombinant Adenoviruses Encoding MART-1 or gp100 Melanoma Antigens
1998
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
2011 StandoutNobel
The Immunobiology of Cancer Immunosurveillance and Immunoediting
2004 Standout
Escape of Human Solid Tumors from T–Cell Recognition: Molecular Mechanisms and Functional Significance
1999
Detection of self-reactive CD8 + T cells with an anergic phenotype in healthy individuals
2014 StandoutScienceNobel
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
2002 StandoutScience
High Frequencies of Naive Melan-a/Mart-1–Specific Cd8+ T Cells in a Large Proportion of Human Histocompatibility Leukocyte Antigen (Hla)-A2 Individuals
1999
Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells.
1997
Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70
2000 StandoutNobel
The Three Es of Cancer Immunoediting
2004 Standout
Effects of Interleukin-12 on the Immune Response to a Multipeptide Vaccine for Resected Metastatic Melanoma
2001
Stimulation of the Glucocorticoid-Induced TNF Receptor Family-Related Receptor on CD8 T Cells Induces Protective and High-Avidity T Cell Responses to Tumor-Specific Antigens
2010 StandoutNobel
Natural Innate and Adaptive Immunity to Cancer
2011 Standout
PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells
2004 StandoutNobel
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
2003
Status of Activation of Circulating Vaccine-Elicited CD8+ T Cells
2000
Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses
2001 StandoutNobel
Agonist Anti-GITR Antibody Enhances Vaccine-Induced CD8+ T-Cell Responses and Tumor Immunity
2006 StandoutNobel
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
2008 StandoutNobel
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
2003 StandoutNobel
Central Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance
2004 Standout
High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993
1999 Standout
Cytotoxic T Lymphocytes Specific for a Nonpolymorphic Proteinase 3 Peptide Preferentially Inhibit Chronic Myeloid Leukemia Colony-Forming Units
1997
A Shift in the Phenotype of Melan-A-Specific CTL Identifies Melanoma Patients with an Active Tumor-Specific Immune Response
2000
Functional Dissociation Between Local and Systemic Immune Response During Anti-Melanoma Peptide Vaccination
1998
HUMAN T CELL RESPONSES AGAINST MELANOMA
2005
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humans
2013 StandoutNobel
HIV Gag mRNA Transfection of Dendritic Cells (DC) Delivers Encoded Antigen to MHC Class I and II Molecules, Causes DC Maturation, and Induces a Potent Human In Vitro Primary Immune Response
2000 StandoutNobel
Overcoming regulatory T‐cell suppression by a lyophilized preparation of Streptococcus pyogenes
2013 StandoutNobel
Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.
1997
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
2002 StandoutNobel
Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation
1999 StandoutNobel
Works of Michael J. Player being referenced
Differential Anti-MART-1/MelanA CTL Activity in Peripheral Blood of HLA-A2 Melanoma Patients in Comparison to Healthy Donors
1996